Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Blinding, shorter duration help reduce placebo responses in systemic therapy trials in AD

17 Dec 2019
Why do placebos work?

In clinical trials of systemic therapy in atopic dermatitis (AD), the integration of double- and triple-blinding can lower placebo responses, according to the results of a systematic review and meta-analysis. Other means of achieving this include balancing of patient sex distribution, disallowing concomitant use of prescription topical therapy and having shorter study durations.

The investigators performed a systematic review and meta-analysis of randomized controlled trials examining the use of systemic therapy in AD published between 2007 and 2018. They searched the databases of Cochrane Library, Medline, Embase, Global Resource for Eczema Trials, Literature of the Latin American and Caribbean Health Sciences and Scopus.

Study selection and data extraction were carried out by two investigators. Multivariable mixed models were generated for the following: Cohen D of Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), numeric rating scale (NRS)–itch and visual analogue scale (VAS)–itch, and Dermatology Life Quality Index (DLQI).

Sixty-four trials met the eligibility criteria. Higher placebo responses were associated with use of concomitant topical therapy prescriptions, study duration ≥3 months and fewer treatment arms for EASI, NRS- and VAS-itch, and DLQI.

For EASI, studies with a higher proportion of male patients, mild-to-moderate mean baseline EASI scores and no blinding had higher placebo responses. For NRS- and VRS-itch, the placebo response was increased in studies with higher proportion of male patients and moderate-to-severe mean itch scores at baseline.

“AD has a variable disease course and intermittent triggers, and responses to topical therapy vary, potentially affecting the magnitude of the placebo response in AD trials,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.